Business Context and Reporting Period
Company: Insulet Corporation (Insulet)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2010
Business Overview: Insulet develops, manufactures, and markets the OmniPod Insulin Management System, a disposable insulin infusion device and a handheld Personal Diabetes Manager (PDM) for insulin-dependent diabetes. The company operates in a single segment, with substantially all revenue generated from sales within the United States. In January 2010, Insulet entered an exclusive distribution agreement with Ypsomed for eleven international countries, with reimbursement approvals obtained in Germany and the UK during the second quarter of 2010.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2010 |
Six Months Ended June 30, 2010 |
Six Months Ended June 30, 2009 |
|---|---|---|---|
| Revenue | $22,937 | $43,744 | $27,086 |
| Gross Profit | $9,886 | $18,271 | $5,164 |
| Gross Margin | 43.1% | 41.8% | 19.1% |
| Operating Loss | $(9,900) | $(20,630) | $(33,917) |
| Net Loss | $(13,711) | $(28,201) | $(39,884) |
| Net Loss Per Share (Basic/Diluted) | $(0.36) | $(0.74) | $(1.43) |
| Cash and Cash Equivalents | $118,071 (as of June 30, 2010) | ||
| Long-Term Debt | $89,136 (as of June 30, 2010) | ||
| Net Cash Used in Operating Activities | $(15,058) (Six Months 2010) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 57% for the three months and 62% for the six months ended June 30, 2010, compared to the same periods in 2009. This growth is attributed to an increased number of patients and higher sales to distributors.
- Gross Margin Expansion: Gross margin improved significantly to 43.1% (Q2 2010) from 21.7% (Q2 2009). This improvement resulted from increased production volumes, raw material cost savings, and volume discounts from suppliers.
- Operating Expenses: Total operating expenses remained relatively flat year-over-year for the six-month period ($38.9M vs $39.1M). Sales and marketing expenses decreased by 10% due to reduced spending on samples and demonstration kits. Research and development expenses increased by 30%, partially due to the expensing of $1.0 million in previously capitalized costs for the next-generation OmniPod.
- Net Loss Reduction: Net loss decreased by 32% for the quarter and 29% for the six-month period compared to 2009, driven primarily by the significant improvement in gross profit.
Guidance, Outlook, Risks, and Unusual Items
- Restatement of Financial Statements: The company restated its financial results for the quarter ended March 31, 2010, and the balance sheet as of December 31, 2009. The restatement corrected the accounting treatment of a September 2009 amendment to its Facility Agreement, reclassifying it from a debt extinguishment to a debt modification. This resulted in a $0.6 million increase in interest expense and net loss for the first quarter of 2010.
- Internal Control Material Weakness: Management identified a material weakness in internal controls over financial reporting related to the accounting for debt modifications. This weakness led to the restatement. Management concluded that disclosure controls and procedures were not effective as of June 30, 2010, solely due to this weakness, though remediation steps were initiated in August 2010.
- Outlook: Management expects revenue to continue increasing in 2010 due to new patient acquisition in the U.S. and international expansion (Germany, UK). The company anticipates continued net losses in the near term as it invests in the next-generation OmniPod and international market entry.
- Liquidity: As of June 30, 2010, the company held $118.1 million in cash and cash equivalents. Management believes this, combined with cash from operations, is sufficient to meet requirements for at least the next twelve months.
- Debt Obligations: The company has $85.0 million in 5.375% Convertible Senior Notes due 2013 and approximately $32.5 million outstanding under a Facility Agreement due September 2012. Significant non-cash interest expense is recorded due to the amortization of debt discounts and financing costs.
Key Facts for Investor Verification
- Restatement Impact: Verify the specific adjustments made to the Q1 2010 results and the December 31, 2009 balance sheet regarding the Facility Agreement modification.
- Internal Controls: Monitor the effectiveness of the remediation plan implemented in August 2010 to address the material weakness in debt accounting.
- International Expansion: Track the progress of the Ypsomed distribution agreement, specifically the timeline for reimbursement approvals and revenue recognition in markets beyond Germany and the UK.
- Next-Generation Product: Assess the timeline and capital requirements for the launch of the next-generation OmniPod, noting the $1.0 million in capitalized costs expensed in Q2 2010.
- Debt Service: Review the cash interest obligations and the amortization schedule for the significant debt discounts associated with the Convertible Notes and Facility Agreement.